Core Insights - The first on-site transaction of medical data products in Henan Province has been successfully completed, involving a collaboration between KingMed Diagnostics and Antu Bioengineering [2][3] - The data product traded is "KingMed Infection Data (Invasive Fungal) Distribution Statistics," which provides critical insights into the prevalence of invasive fungal infections across different regions and times, aiding in the development of prevention strategies and treatment optimization [2] Group 1: Transaction Details - The transaction marks a significant step in the compliant circulation of medical data within the healthcare sector [3] - The data product integrates detection information of specific fungal infections nationwide, reflecting epidemiological characteristics [2] Group 2: Company Profiles - Antu Bioengineering, founded in 1998 and listed on the Shanghai Stock Exchange in September 2016, is the first domestic company to focus on the research and manufacturing of in vitro diagnostic products [3] - KingMed Diagnostics is a high-tech service enterprise specializing in third-party medical testing and pathology diagnosis, providing leading diagnostic information integration services across various medical institutions in China [3]